Triger 1980.

Methods	Randomised clinical trial.
Participants	Country: UK. Number randomised: 35. Post‐randomisation dropouts: not stated. Revised sample size: 35. Mean age: not stated. Females: not stated. Symptomatic participants: not stated. AMA positive: not stated. Responders: not stated. Mean follow‐up period (for all groups): not stated. Inclusion criteria Symptom status: not stated. AMA status: not stated. Response status: not stated.
Interventions	Participants were randomly assigned to 2 groups. Group 1: D‐penicillamine (n = not stated). Further details: D‐penicillamine: 250 mg to 875 mg (escalating dose). Group 2: placebo (n = not stated).
Outcomes	Mortality.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: information not available.
Allocation concealment (selection bias)	Unclear risk	Comment: information not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: in this double‐blind trial, unclear whether the placebo was identical to active treatment.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: in this double‐blind trial, unclear whether the placebo was identical to active treatment.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: information not available.
Selective reporting (reporting bias)	High risk	Comment: adverse events not reported.
For‐profit bias	High risk	Quote: "The UDCA and placebo tablets were generously donated by Thames Laboratories, Wrexham, Wales".
Other bias	Low risk	Comment: no other source of bias.